Is Dexcom Stock A Buy Now?

Core Insights - DexCom (DXCM) stock is currently trading within a support range of $55.31 to $61.13, where it has historically bounced back significantly, achieving an average peak return of 66.2% over the past decade [2]. Company Overview - DexCom specializes in continuous glucose monitoring systems, including the next-generation G7 CGM, which is available for use in the U.S. and internationally [4]. - The company has demonstrated a revenue growth rate of 9.3% over the last twelve months (LTM) and an average growth rate of 17.3% over the past three years [5]. - DexCom has a free cash flow margin of nearly 13.3% and an operating margin of 16.0% LTM [5]. Historical Performance - The stock has experienced significant declines during major market downturns, including a drop of nearly 87% during the Global Financial Crisis, 48% in the 2018 correction, and 58% during the inflation spike, as well as a 37% decline during the Covid pandemic [4][5]. - Despite these downturns, the stock has shown resilience and has recovered from past revenue shocks, with the lowest annual revenue growth in the last three years being 9.3% [5]. Valuation Metrics - DexCom stock is currently valued at a price-to-earnings (PE) multiple of 39.9 [5].